BC Week In Review | Sep 8, 2017
Company News

J&J ends deal for Macrogenics' duvortuxizumab

MacroGenics Inc. (NASDAQ:MGNX) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) terminated its license to duvortuxizumab (MGD011), a bispecific antibody against CD19 and CD3 . MacroGenics said the termination will not affect a...
BC Extra | Sep 1, 2017
Company News

J&J ends deal for MacroGenics' duvortuxizumab

MacroGenics Inc. (NASDAQ:MGNX) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) terminated its license to duvortuxizumab ( MGD011 ), a bispecific antibody against CD19 and CD3 . MacroGenics said the termination will not affect...
BC Extra | May 19, 2016
Company News

J&J, MacroGenics in second antibody deal

MacroGenics Inc. (NASDAQ:MGNX) jumped $3.02 (17%) to $21.06 on Wednesday after granting the Janssen Biotech Inc. unit of Johnson & Johnson exclusive, worldwide rights to MGD015, a preclinical bispecific antibody against CD3 and an undisclosed...
BC Week In Review | Sep 21, 2015
Company News

MacroGenics, J&J deal

MacroGenics received a $10 million milestone payment from Johnson & Johnson’s Janssen Biotech Inc. unit under a 2014 deal granting the unit exclusive, worldwide rights to MGD011 ( JNJ-64052781 ). The milestone was triggered by the...
BC Week In Review | Sep 7, 2015
Clinical News

MGD011: Phase I started

Johnson & Johnson’s Janssen Biotech Inc. unit began an open-label, dose-escalation, dose-expansion, international Phase I trial to evaluate IV MGD011, starting at a 0.5 ng/kg dose, in about 140 patients. The start of the trial...
BC Week In Review | Jan 5, 2015
Company News

MacroGenics, J&J deal

MacroGenics will grant Johnson & Johnson’s Janssen Biotech Inc. unit exclusive, worldwide rights to preclinical candidate MGD011 . The compound is a bispecific antibody against CD19 and CD3 developed using Dual-Affinity Re-Targeting (DART) technology. Janssen plans...
BC Extra | Dec 23, 2014
Company News

MacroGenics, Janssen enter DART deal

MacroGenics Inc. (NASDAQ:MGNX) climbed $4.05 (12%) to $38.58 after announcing it will receive $125 million up front in a deal granting the Janssen unit of Johnson & Johnson (NYSE:JNJ) exclusive worldwide rights to preclinical compound...
Items per page:
1 - 7 of 7